Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormonereceptor+/HER2-metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study

Simple item page
dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorJimenez, M. Martin
dc.contributor.authorZielinski, C.
dc.contributor.authorRuiz-Borrego, M.
dc.contributor.authorCarrasco, E.
dc.contributor.authorCiruelos, E. M.
dc.contributor.authorMunoz, M.
dc.contributor.authorBermejo, B.
dc.contributor.authorMargeli, M.
dc.contributor.authorCsoszi, T.
dc.contributor.authorAnton, A.
dc.contributor.authorTurner, N.
dc.contributor.authorCasas, M. I.
dc.contributor.authorMorales, S.
dc.contributor.authorAlba, E.
dc.contributor.authorCalvo, L.
dc.contributor.authorDe la Haba, J.
dc.contributor.authorRamos, M.
dc.contributor.authorCorsaro, M.
dc.contributor.authorKahan, Z.
dc.contributor.authorGil-Gil, M.
dc.contributor.authoraffiliation[Jimenez, M. Martin] Univ Gregorio Maranon, Hosp Gen, GEICAM Breast Canc Grp, CIBERONCI SCIII,Med Dept,Serv Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Zielinski, C.] Med Univ Wien, Vienna Gen Hosp AKH, Oncol Dept, CECOG, Vienna, Austria
dc.contributor.authoraffiliation[Ruiz-Borrego, M.] Hosp Univ Virgen Rocio, GEICAM Breast Canc Grp, Oncol Dept, Seville, Spain
dc.contributor.authoraffiliation[Carrasco, E.] GEICAM Breast Canc Grp, Sci Dept, Madrid, Spain
dc.contributor.authoraffiliation[Ciruelos, E. M.] Hosp Univ 12 Octubre, GEICAM Breast Canc Grp, HM Hosp Madrid, Med Oncol Dept,SOLTI, Madrid, Spain
dc.contributor.authoraffiliation[Munoz, M.] Hosp Univ Clin, GEICAM Breast Canc Grp, Med Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Bermejo, B.] Hosp Clin Univ Valencia, Biomed Res Inst INCLIVA, GEICAM Breast Canc Grp, Oncol Dept, Valencia, Spain
dc.contributor.authoraffiliation[Margeli, M.] Hosp Univ Germans Trias i Pujol, GEICAM Breast Canc Grp, Inst Catala Oncol, Badalona Appl Res Grp Oncol ARGO Grp,Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Csoszi, T.] CECOG, Onkol Kozpont, Hetenyi Geza Korhaz, Onkol Kozpont, Szolnok, Hungary
dc.contributor.authoraffiliation[Anton, A.] Hosp Univ Miguel Servet, Oncol Dept, Inst Invest Sanitaria Aragon IISA, GEICAM Breast Canc Grp, Zaragoza, Spain
dc.contributor.authoraffiliation[Turner, N.] Inst Canc Res & Royal Marsden, Oncol Dept, London, England
dc.contributor.authoraffiliation[Casas, M. I.] GEICAM Breast Canc Grp, Statist Dept, Madrid, Spain
dc.contributor.authoraffiliation[Morales, S.] Hosp Arnau Vilanova, Oncol Dept, GEICAM Breast Canc Grp, Lleida, Spain
dc.contributor.authoraffiliation[Alba, E.] Hosp Reg & Virgen Victoria, GEICAM Breast Canc Grp, CIBERONCI SCIII, UGCI Med Oncol,Oncol Dept,IBIMA, Malaga, Spain
dc.contributor.authoraffiliation[Calvo, L.] Complejo Hosp Univ A Coruna, GEICAM Breast Canc Grp, Oncol Dept, La Coruna, Spain
dc.contributor.authoraffiliation[De la Haba, J.] Univ Cordoba, Hosp Reina Sofia Hosp, Inst Maimonides Invest Biomed, Oncol Dept,GEICAM Breast Cncer Grp, Cordoba, Spain
dc.contributor.authoraffiliation[Ramos, M.] GEICAM Breast Canc Grp, Ctr Oncol Galicia, Oncol Dept, La Coruna, Spain
dc.contributor.authoraffiliation[Corsaro, M.] Pfizer Inc, Oncol Dept, Milan, Italy
dc.contributor.authoraffiliation[Kahan, Z.] Univ Szeged, Dept Oncotherapy, Oncol Dept, CECOG, Szeged, Hungary
dc.contributor.authoraffiliation[Gil-Gil, M.] Inst Catala Oncol ICO, Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Gil-Gil, M.] GEICAM Breast Canc Grp, IDIBELL, Barcelona, Spain
dc.contributor.funderPfizer
dc.contributor.funderAstraZeneca
dc.date.accessioned2025-01-07T13:36:40Z
dc.date.available2025-01-07T13:36:40Z
dc.date.issued2021-09-21
dc.identifier.doi10.1016/j.annonc.2021.08.512
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.512
dc.identifier.urihttps://hdl.handle.net/10668/25687
dc.identifier.wosID700527700208
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS457-S458
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleOverall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormonereceptor+/HER2-metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Reina Sofía
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía